本页面由Tiger Trade Technology Pte. Ltd.提供服务

CytoMed Therapeutics Limited

1.04
-0.0300-2.80%
成交量:2,336.00
成交额:2,450.29
市值:1,220.30万
市盈率:-4.16
高:1.06
开:1.06
低:1.04
收:1.07
52周最高:3.68
52周最低:0.7282
股本:1,173.37万
流通股本:598.81万
量比:0.32
换手率:0.04%
股息:- -
股息率:- -
每股收益(TTM):-0.2499
每股收益(LYR):-0.1598
净资产收益率:-42.33%
总资产收益率:-22.85%
市净率:2.16
市盈率(LYR):-6.51

数据加载中...

2026/02/12

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/09/22

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/06/23

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/06/20

SEC问询函

Form CORRESP - Correspondence
2025/04/28

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2025/03/24

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2025/01/06

员工持股计划

Form S-8 - Securities to be offered to employees in employee benefit plans
2024/11/04

关联方拟减持公告

Form 144 - Report of proposed sale of securities
2024/05/23

超过5%披露

Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]
2024/04/22

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2024/02/15

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/05/19

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/05/01

年度报告

Form 20-F - Annual and transition report of foreign private issuers [Sections 13 or 15(d)]
2023/04/24

超过5%披露

Form SC 13G - Statement of acquisition of beneficial ownership by individuals
2023/04/21

超过5%披露

Form SC 13D - General statement of acquisition of beneficial ownership
2023/03/31

SEC问询函

Form CORRESP - Correspondence
2023/03/31

SEC问询函

Form CORRESP - Correspondence